Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2012 February;60(1) > Minerva Cardioangiologica 2012 February;60(1):95-100

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


eTOC

 

  INTERVENTIONAL CARDIOLOGY


Minerva Cardioangiologica 2012 February;60(1):95-100

language: English

Glycoprotein IIb/IIIa inhibitors and bivalirudin in patients undergoing percutaneous coronary intervention

Mahmoudi M., Waksman R.

Division of Cardiology, Department of Internal Medicine, Washington Hospital Center, Washington, DC, USA


PDF  


Percutaneous coronary intervention (PCI) is currently the standard of care for patients presenting with acute coronary syndrome (ACS), as well those patients with “stable” angina who have failed medical therapy in whom PCI is an acceptable alternative to surgical revascularization. The aim of adjunctive antiplatelet and antithrombotic therapy during PCI is to alleviate the risks associated with platelet activation and aggregation, iatrogenic plaque rupture, and thrombus formation during. The aim of this review is to summarize the evidence that has emerged from the randomized studies comparing a strategy combining heparin and a glycoprotein IIb/IIIa inhibitor (GPI) with that of bivalirudin in patients undergoing elective and urgent PCI.

top of page

Publication History

Cite this article as

Corresponding author e-mail

ron.waksman@medstar.net